Novartis Gilenya Patient Diagnosed With Rare Infection
This article is for subscribers only.
A patient taking Novartis AG’s Gilenya multiple sclerosis pill contracted a potentially deadly brain infection, adding to concern that the medicine may lose ground to a competing product.
Unlike a previous case, the patient hadn’t taken Biogen Idec Inc.’s Tysabri injection, an MS drug that increases the risk of the viral infection, known as progressive multifocal leukoencephalopathy, Novartis said in an e-mail today.